TD Cowen analyst Tara Bancroft has maintained their bullish stance on CELC stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tara Bancroft’s rating is based on the promising results from Celcuity’s Phase III VIKTORIA-1 trial, which demonstrated a significant improvement in progression-free survival (PFS) for patients treated with the geda triplet therapy. The trial showed an unprecedented hazard ratio (HR) of 0.24, indicating a notable extension of median PFS to 9.3 months compared to 2.0 months for those on fulvestrant alone. This outcome suggests that the geda triplet could become a standard therapy for second-line WT patients.
Furthermore, Celcuity’s management is confident in their upcoming New Drug Application (NDA) submission, expected in Q4, supported by consistent data across key patient subgroups. The company is also preparing to expand its commercial operations to support the anticipated adoption of the therapy. The positive overall survival trend, despite high crossover levels, adds to the FDA’s likely support, enhancing the stock’s potential value and justifying the Buy rating.
In another report released today, Needham also maintained a Buy rating on the stock with a $70.00 price target.